For more than two decades, Shearman & Sterling has been a leader in the healthcare industry, having successfully represented clients across the globe in every sector of the industry, including large pharmaceutical, specialty and generic pharmaceutical, life sciences, biotechnology, medical devices and healthcare services. Its clients include some of the world’s largest healthcare companies and promising startup and research companies, as well as investment banks and private equity firms.
Shearman & Sterling was among the first global law firms to establish a Beijing office approved and licensed by China’s Ministry of Justice. Since then, as China has emerged as a global economic powerhouse, it has worked closely alongside its clients as their businesses in China developed and expanded. Today, in addition to international investors and investment banks, its clients include Chinese state-owned enterprises and small- and medium-sized private Chinese enterprises across a broad spectrum of industries.
Its lawyers have represented clients on many groundbreaking transactions. Since advising on the first Sino-foreign joint venture between a Chinese entity and a US partner 20 years ago, it has continued to do precedent-setting work. This includes the first successful M&A transaction done under the new Chinese M&A rules, and the first power project refinancing in the People’s Republic of China completed by a wholly foreign-owned enterprise.
Expanding upon its considerable China practice, Shearman & Sterling opened an office in Shanghai in June 2007. Fully integrated with its established offices in Beijing and Hong Kong, the Shanghai office allows it to better serve clients in Central and Southern China and strengthen its successful project development, finance, capital markets, and M&A work in China.